Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes.,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-01-07 , DOI: 10.1111/jdi.13195
Masanari Shiramoto ₁ , Risa Nasu ₂ , Tomonori Oura ₂ , Makoto Imori ₂ , Kenji Ohwaki ₂

Affiliation

Ultra‐rapid lispro (URLi) is a novel ultra‐rapid mealtime insulin. This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog^®) in Japanese patients with type 1 diabetes mellitus.

中文翻译：

与 Humalog® 相比，在日本 1 型糖尿病患者中，Ultra-Rapid Lispro 可加速赖脯胰岛素吸收并加快早期胰岛素作用。

超快速赖脯胰岛素 (URLi) 是一种新型超快速进餐胰岛素。本研究比较了日本 1 型糖尿病患者中 URLi 和赖脯胰岛素 (Humalog ^® ) 的药代动力学和糖动力学特征、安全性和耐受性。

更新日期：2020-01-07

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11